

RESEARCH ARTICLE

View Article Online
View Journal

Cite this: DOI: 10.1039/d6qo00226a

Defining substrate specificities of *N*-acetylglucosamine-6-*O*-sulfotransferases for enzymatic modular assembly of sulfated *O*-glycans

 Shuquan Fan, Jinghua Han, Tangliang Shen, Mohammad Hossein Shabahang, Zhenming Du, Jun Pan, Guitao Bai, Shumin Bao, Avinash Ittuveetil and Lei Li *

Sulfated *O*-glycans are widely distributed and play key roles in a wide range of physiological and disease processes, yet their synthesis remains challenging due to difficulties in regioselective sulfation. Here, we systematically characterized two human GlcNAc-6-*O*-sulfotransferases, CHST2 and CHST6, revealing their strong preference towards *O*-glycans (including *O*-GalNAc and *O*-mannosyl glycans) over *N*-glycans and poly-LacNAc chains. Both enzymes favored β 1-6 branched GlcNAc residues, with CHST6 showing higher activity and broader substrate tolerance than CHST2. Guided by these insights, we established a modular enzymatic assembly platform for efficient synthesis of 32 well-defined sulfated *O*-GalNAc, *O*-mannosyl glycans, and *O*-glycopeptides. This streamlined strategy enables versatile access to sulfated *O*-glycans and provides a general route for constructing other classes of sulfated glycans.

Received 22nd February 2026,

Accepted 11th April 2026

DOI: 10.1039/d6qo00226a

rsc.li/frontiers-organic

Introduction

Sulfation is the most abundant glycan modification, which significantly impacts the structure and functions of residing glycans.¹ The sulfated glycans of the linear glycosaminoglycan (GAG) class, including heparan sulfate (HS), chondroitin sulfate (CS), and keratan sulfate (KS), are found to be ubiquitously expressed on the cell surfaces of all mammals, where they regulate extracellular cell signaling, growth and homeostasis, and provide structural support.^{2,3} Importantly, sulfation is not restricted to linear GAGs, but is also frequently identified on complex *O*-glycans, which play critical roles in a variety of biological processes. For example, peripheral node addressin (PNAd), a set of sialomucins including GlyCAM-1 and CD34, carries *O*-GalNAc glycans that present the 6-sulfated sialyl-Lewis X (6-sulfo-sLe^x) epitope on core 2 and extended core 1 branches.^{4–6} Such *O*-glycans function as ligands for L-selectin, mediating lymphocyte homing and inflammatory responses.^{7,8} These ligands were often identified using a MECA-79 mAb that specifically recognizes a sulfated extended core-1 structure.⁴ In addition, highly sulfated *O*-glycans correlate with various diseases, e.g., abnormally sulfated mucins appear to be central to respiratory infections in patients with cystic fibrosis,⁹ and numerous sulfated *O*-GalNAc glycans have been identified on a

variety of tumor cells and tissues,^{10–12} some as tumor biomarker candidates.¹³ A recent study identified 83 *O*-glycan compositions on MUC2, MUC5AC, and MUC5B, among which 51 were mono-sulfated and 20 were di-sulfated,¹⁴ further underscoring the widespread prevalence of sulfated *O*-glycans.^{15–18} These *O*-glycans, together with non-sulfated ones, coat the colon surface to form a protective barrier against gut microbes.¹⁹ *O*-mannosyl glycans, accounting for over 30% of all *O*-glycans in brain tissues,²⁰ have also been found to carry sulfate groups. These structures typically contain the HNK-1 epitope²¹ and play important roles in brain development and remyelination.^{22,23} Notably, recent studies have identified core m1 and core m2 *O*-mannosyl glycans with distinct sulfation patterns in brain tissues²⁴ and mucins.¹⁹

All sulfations on *N*/*O*-glycans are oxygen-linked (*O*-sulfation), with only a few sulfated motifs being documented (Fig. 1A). Among these, 6-sulfo-GlcNAc, 6-sulfo-Gal, and 3-sulfo-Gal are common to both *O*-glycans and *N*-glycans,²⁵ whereas 4-sulfo-GalNAc has been reported almost exclusively on *N*-glycans, capping the 4'-sulfated-LDN epitope.^{25,26} The motif 3-sulfo-GlcA is a characteristic of the HNK-1 epitope often terminating *O*-mannosyl glycans, *N*-glycans, and glycolipids on neural tissues.²⁷ Sialic acids can also be *O*-sulfated at the C8 position (8-sulfo-Neu5Ac or 8-sulfo-Neu5Gc), which were found in various vertebrate cells and tissues, even though underlying glycan scaffolds have yet to be defined.²⁸ Despite limited sulfation motifs, sulfated *O*-glycans are highly diversified. Such heterogeneity arises from the extensive branching

Department of Chemistry and Center for Diagnostics & Therapeutics, Georgia State University, Atlanta, GA 30303, USA. E-mail: lli22@gsu.edu






Fig. 1 Common non-GAG sulfations and sulfated O-glycans synthesized in this work. (A) Typical sulfation motifs found on mammalian O-glycans; (B) examples of identified sulfated O-glycan epitopes; and (C) sulfated O-glycans and glycopeptides prepared in this study. GlcNAc, N-acetylglucosamine; Gal, galactose; GalNAc, N-acetylgalactosamine; Man, mannose; Neu5Ac, N-acetylneuraminic acid; GlcA, glucuronic acid; L-Fuc, L-fucose; Ser, serine; Thr, threonine; and Fmoc, fluorenylmethyloxycarbonyl.

and varied O-glycan core structures, offering numerous sulfation sites. Nevertheless, recent advances have highlighted diverse functional roles of sulfated non-GAGs, particularly their interactions with Siglecs and other glycan-binding proteins (GBPs),^{29–31} although detailed structure–function relationships for individual structures remain largely underexplored.

The widespread occurrence and diverse functions of sulfated glycans have spurred significant recent interest in synthesizing these molecules. For instance, a variety of sulfated glycan determinants have been chemoenzymatically synthesized in which sulfates are chemically installed onto primary alcohols (C6-OH) of Gal, GlcNAc, or Glc residues due to their relatively high reactivity.^{32,33} Chemoenzymatic synthesis of gangliosides with 3-sulfo-Gal,

6-sulfo-GalNAc, or the HNK-1 epitope, core 2 O-GalNAc glycan with 6-sulfo-GlcNAc, and HNK-1-presenting O-mannosyl glycans was achieved, where sulfates were also chemically installed.^{34–38} Biosynthetically, sulfates are transferred from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to specific positions of glycans by sulfotransferases (sulfoTs). Recent advances in the expression and application of sulfoTs have enabled the synthesis of complex sulfated glycans. For example, Boons and coworkers prepared an array of KS structures utilizing CHST1 and CHST2.^{39,40} Wang and coworkers applied CHST1, CHST2, and Gal3ST2 for the enzymatic synthesis of sulfated biantennary N-glycans.^{41,42} During the preparation of this work, Wen *et al.* reported the *de novo* synthesis of sulfated multi-antennary N-glycans using similar sulfoTs as well as CHST6.⁴³ In a different approach, Withers and co-workers recently reported



an engineered 6-sulfo-GlcNAcase capable of directly transferring 6-sulfo-GlcNAc to generate a few sulfated *N*-glycans and extended core 1 *O*-glycans, including the MECA-79 epitope.⁴⁴ Further application of these engineered glycosidases in the synthesis of sulfated complex glycans remains to be evaluated due to the lack of specificity towards various acceptors. Nevertheless, chemoenzymatic synthesis of well-defined sulfated *O*-glycans is scarce,³⁸ especially complex structures such as the di-sulfated biantennary *O*-GalNAc glycan found in GlyCAM-1 (Fig. 1B). We have focused our efforts on developing synthetic strategies to access *O*-glycans and glycopeptides.^{45–48} In this work, we target sulfated *O*-glycans, specifically those bearing the abundant 6-sulfo-GlcNAc motif.

In vivo, *N*-acetylglucosamine-6-*O*-sulfotransferase (GlcNAc6ST) catalyzes the 6-*O*-sulfation of non-reducing end GlcNAc residues to generate 6-sulfo-GlcNAc in Golgi.^{49–52} Humans have five GlcNAc6ST isoenzymes, CHST2 (GlcNAc6ST-1), CHST4 (GlcNAc6ST-2), CHST5 (GlcNAc6ST-3), CHST6 (GlcNAc6ST-5), and CHST7 (GlcNAc6ST-4). CHST2 was first identified in human bronchial mucosa, which sulfates the terminal branching GlcNAc on the core 2 *O*-GalNAc glycan.⁵¹ Substrate specificity studies using radiolabeled PAPS demonstrated similar activity to *O*-mannosyl glycans (GlcNAc β 1-2Man and GlcNAc β 1-6Man), but not to *O*-GalNAc core 3 (GlcNAc β 1-3GalNAc).⁵⁰ Its activity toward a linear keratan pentasaccharide was substantially lower,⁵⁰ although recent studies successfully employed it to synthesize KS.^{39,40} In the context of biantennary *N*-glycans, Wang and coworkers demonstrated that CHST2 preferentially sulfates the GlcNAc residue on the α 1-3Man branch, although the α 1-6Man branch can also be sulfated with excess PAPS and prolonged incubation.^{41,42} CHST4, also known as HEC-GalNAc6ST, has a similar substrate specificity (except that

it also sulfates *O*-GalNAc core 3) but lower activity.⁵⁰ CHST5 and CHST6, also known as I-GINAc6ST and C-GlcNAc6ST, respectively, showed the highest activity toward *O*-GalNAc core 2 but also recognized multi-branched *N*-glycans and *O*-GalNAc extended core 1.⁴⁹ Lastly, CHST7 not only preferentially acts on mannose-linked GlcNAc but can also act on *O*-GalNAc core 2 and the GalNAc residues of chondroitin, and therefore it is also referred to as C6ST-2.^{53,54} Nevertheless, nearly all prior characterization studies relied on radiolabeled PAPS, which occasionally yielded inconsistent results. A clear understanding of their substrate specificity toward diverse glycan structures is highly demanded to guide synthetic efforts. In this work, we overexpressed human CHST2 and CHST6, explored their activities toward 20 acceptor substrates, and discovered their strong preference toward *O*-glycans, particularly GlcNAc β 1-6 branches. Using both sulfoTs and eight robust glycosyltransferases (GTs), we achieved enzymatic modular assembly of 32 sulfated *O*-glycans and *O*-glycopeptides (Fig. 1C).

Results and discussion

CHST2 and CHST6 strongly prefer the GlcNAc β 1-6 branch of *O*-glycans

Among the five GlcNAc6STs, CHST2 and CHST6 were selected for expression and activity assay due to their relatively high expression levels.⁵⁵ They were expressed in HEK293 cells (see Methods for details), yielding 65 mg L⁻¹ and 15 mg L⁻¹ CHST2 and CHST6, respectively, following one-step Ni-NTA affinity purification (Fig. S1). Both enzymes were evaluated for their substrate specificity against a panel of 20 glycan structures




Fig. 2 Substrate specificity studies of CHST2 and CHST6. A. Structures of the tested acceptor substrates; B. relative activity of the sulfoTs toward the 20 acceptors. LN, LacNAc; Ser, serine; Thr, threonine; and Fmoc, 9-fluorenylmethoxycarbonyl.



(Fig. 2A), including *N*-glycans (**1**, **2**), linear poly-LacNAc oligosaccharides (**3–8**),⁵⁶ mucin-type *O*-glycan cores (**9–16**),⁴⁶ and *O*-mannosyl glycans (**17–20**).⁴⁷ As shown in Fig. 2B and Table S1, neither CHST2 nor CHST6 sulfated LacNAc (**4**), Tn (**9**), or T-antigen (**10**), consistent with their strict recognition of non-reducing terminal GlcNAc residues.^{49–52} CHST2 sulfates both G0 (**1**) and G1 (**2**) with low but comparable activities (1.34 and 1.02 nmol min⁻¹ mg⁻¹). A di-sulfated product was not observed for G0, consistent with previous reports, which suggested a preference to the GlcNAc β 1-2Man α 1-3 branch.^{41,42} The activity of CHST2 toward the GlcNAc monosaccharide (**3**) is approximately two-fold (2.75 nmol min⁻¹ mg⁻¹) that toward *N*-glycans. However, its activity toward terminal GlcNAc on linear poly-LacNAc chains (**5–7**) is over 10-fold lower (0.08–0.28 nmol min⁻¹ mg⁻¹), suggesting that CHST2 is unlikely to be responsible for the synthesis of keratan sulfates.⁵⁰ Surprisingly, CHST2 showed much higher activity toward *O*-GalNAc and *O*-mannosyl glycans bearing GlcNAc β 1-6 branches (**12**, **15**, **16**, **18**, and **19**), reaching 10.54–17.26 nmol min⁻¹ mg⁻¹, about 8–12 fold that toward *N*-glycan G0 (Fig. 2B). In contrast, CHST2 exhibited negligible activity toward *O*-GalNAc extended core 1 (**11**), core 3 (**14**), *O*-mannosyl core m1 (**17**), and compound **20**, all of which lack a terminal unmodified β 1,6-linked GlcNAc residue. Notably, its sulfation preference does not extend to all β 1-6linked GlcNAc, as the activity toward compound **8**, poly-LacNAc presenting an I-branched GlcNAc, was negligible. Another surprising observation was that the attached amino acid affected activity, with Thr-linked core 2 (**13**) exhibiting twice the activity (35.27 nmol min⁻¹ mg⁻¹) of Ser-linked core 2 (**12**, 16.52 nmol min⁻¹ mg⁻¹). Collectively, these results indicate that CHST2 strongly prefers β 1-6linked branching GlcNAc on *O*-glycans.

CHST6 displayed broader substrate specificity and higher activity than CHST2 toward most tested substrates, with only exceptions being *N*-glycans G0 and G1 (Fig. 2B and Table S1). CHST6 showed substantially higher activity than CHST2 toward linear poly-LacNAc chains (**5–7**). For example, its activity toward trisaccharide **5** was 22-fold higher (6.09 nmol min⁻¹ mg⁻¹) than that of CHST2. Interestingly, the activity of CHST6 declined progressively with increased lengths of poly-LacNAc chains (relative activities of 12.74, 6.09, 4.73, and 1.72 nmol min⁻¹ mg⁻¹ towards monosaccharide (**3**), trisaccharide (**5**), pentasaccharide (**6**), and heptasaccharide (**7**)). This result suggests a sensitivity to the glycan chain length in CHST6 substrate recognition. Similar to CHST2, CHST6 strongly prefers *O*-GalNAc and *O*-mannosyl glycans with β 1-6linked branching GlcNAc (**12**, **15**, **16**, **18**, and **19**), and its activities are approximately two-fold those of CHST2, with the highest relative activity observed toward *O*-GalNAc core 4 (**15**), reaching 47.86 nmol min⁻¹ mg⁻¹. Notably, CHST6 also showed medium activity (5.63 nmol min⁻¹ mg⁻¹) toward extended core 1 **11**, about 15-fold that of CHST2 (0.36 nmol min⁻¹ mg⁻¹). Meanwhile, CHST6 could sulfate *O*-GalNAc core 3 (**14**), *O*-mannosyl core m1 (**17**) and compound **18**, although with lower activities (1.39–1.7 nmol min⁻¹ mg⁻¹), which are comparable to those of *N*-glycans, suggesting its broader substrate specificity.

Taken together, while both CHST2 and CHST6 have been applied for the synthesis of sulfated *N*-glycans,^{41–43} they strongly prefer the β 1-6linked GlcNAc branches on *O*-glycans. In comparison, CHST2 shows relatively high activity toward *N*-glycans, whereas CHST6 displays higher activity toward all other tested substrates, particularly less preferred structures such as *O*-GalNAc extended core 1, core 3, *O*-mannosyl core m1, and poly-LacNAc chains, making it a superior synthetic catalyst toward various sulfated *O*-glycans and keratan sulfates.

Enzymatic modular assembly of *O*-GalNAc glycans with mono- and di-sulfation

Knowing the detailed substrate specificities of CHST2 and CHST6, we devised an enzymatic modular assembly strategy to prepare diverse sulfated *O*-GalNAc glycans (Fig. 3). The enzymatic assembly began with chemically prepared *O*-GalNAc core 1-Ser (Fmoc-protected) (**10**).⁴⁶ The hydrophobic, UV-detectable Fmoc group facilitated reaction monitoring and enabled reverse-phase (RP) chromatography purification.⁵⁶ To synthesize extended core 1 structures with 6-*O*-sulfation (**21–25**), we first employed a β 1-3GlcNAcylation module (module N1) to produce **11**. The module includes *Helicobacter pylori* β 1-3-*N*-acetylglucosaminyltransferase (HpLgtA)⁵⁷ and the sugar donor UDP-GlcNAc. Although a previous report achieved 90% yield when core 1 was attached to threonine (Thr),⁵⁷ our initial reactions gave only moderate conversion (44%), suggesting that the activity of HpLgtA may be influenced by attached amino acids or the bulky Fmoc group. A homolog from *Neisseria meningitidis* (NmLgtA)⁵⁸ was also tested, which gave minimum conversions. Nevertheless, by supplying 5 fold sugar donor, and extending the reaction time, a good yield of 73% was achieved using HpLgtA, producing 27 mg of **11** after a one-step RP chromatography purification. With compound **11** in hand, CHST6 was selected to sulfate GlcNAc in the presence of 1.5 equivalents of PAPS (module Su6), given its superior activity, affording **21** in a good yield of 78%. NMR analysis of **21** confirmed the 6-*O*-sulfation on GlcNAc (SI). Subsequent sequential β 1-4galactosylation (module G enabled by *H. pylori* β 1-4galactosyltransferase HpLgtB⁵⁹), α 2-3sialylation (module S1 enabled by human ST3Gal4), and α 1-3fucosylation (module F1 enabled by *H. pylori* α 1-3fucosyltransferase Hp3FT⁶⁰) of **21** produced **22** (MECA-79 epitope), **24**, and **25**, respectively, in satisfactory yields of 78–87%. Finally, module F1 catalyzed fucosylation of **22** afforded **23** in 80% yield. These results indicate that 6-sulfo-GlcNAc is well tolerated by these GTs.

We next aimed to synthesize *O*-GalNAc core 2 and biantennary core 2 glycans with defined sulfation patterns (Fig. 3). Previously, we reported the chemical synthesis of core 2 at a 300 mg scale, which required additional chemical glycosylation steps from core 1.⁴⁶ Alternatively, the enzymatic synthesis of core 2 was attempted in this work, using the branching enzyme GCNT1 expressed in HEK293 cells (18 mg L⁻¹ culture) (Fig. S1). This approach (module N2) afforded 145 mg of core 2 (compound **12**) in an excellent yield of 93%. Subsequent 6-*O*-






Fig. 3 Enzymatic modular assembly of sulfated O-GalNAc glycans. Module N1, β 1-3-GlcNAcylation catalyzed by *H. pylori* β 1-3-N-acetylglucosaminyltransferase (HpLgtA)⁵⁷ in the presence of uridine-diphosphate-GlcNAc (UDP-GlcNAc); module N2, β 1-6GlcNAcylation catalyzed by human GCNT1 in the presence of UDP-GlcNAc; module G, β 1-4galactosylation catalyzed by *H. pylori* β 1-4galactosyltransferase (HpLgtB)⁵⁹ in the presence of UDP-Gal; module Su2, GlcNAc-6-O-sulfation catalyzed by CHST2 in the presence of PAPS; module Su6, GlcNAc-6-O-sulfation catalyzed by CHST6 in the presence of PAPS; module F1, α 1-3 fucosylation catalyzed by *H. pylori* α 1-3/4 fucosyltransferase C-terminal 66 amino acid truncation (Hp3FT)⁶⁰ in the presence of guanosine 5'-diphospho-L-fucose (GDP-Fuc); module F2, α 1-2fucosylation catalyzed by *H. mustelae* α 1-2fucosyltransferase (Hm2FT)⁶¹ in the presence of GDP-Fuc; module S1, α 2-3sialylation catalyzed by human ST3Gal4 in the presence of cytidine 5'-monophospho-N-acetylneuraminic acid (CMP-Neu5Ac); module S2, α 2-3sialylation catalyzed by human ST3Gal1 in the presence of CMP-Neu5Ac; module S3, α 2-6sialylation catalyzed by *P. damsela* α 2-6sialyltransferase (Pd26ST)⁶⁰ in the presence of CMP-Neu5Ac.

sulfation of β 1-6GlcNAc to produce 26 was achieved by module Su2 (catalyzed by CHST2) in an excellent yield of 91%. CHST2 was selected, given its much higher expression level (four times that of CHST6). With 26 in hand, mono-sulfated structures (27–33) were prepared through enzymatic modular assembly with well programmed module sequences (Fig. 3). For example, α 1-2fucosylation (module F2 catalyzed by *H. mustelae* α 1-2fucosyltransferase Hm2FT⁶¹) and subsequent

β 1-4galactosylation (module G) produced 27 and 28 in 92% and 84% yields, respectively. To synthesize 29, human ST3Gal1 (Fig. S1) was employed (module S2) instead of a previously widely used *Pasteurella multocida* α 2-3sialyltransferase 1 mutant, M144D, due to its residual hydrolysis activity.⁶² Later β 1-4galactosylation (module G), α 2-6sialylation (module S3 catalyzed by *Photobacterium damsela* α 2-6sialyltransferase Pd26ST),⁶⁰ α 2-3sialylation (module S1), and α 1-3fucosylation



(module F1) of the β 1-6GlcNAc branch on **29** afforded **30–33** in very good yields (83–87%).

The synthesis of biantennary core 2 structures was initiated by β 1-3GlcNAcylation (module N1) of **26** in the presence of excess amounts of donor, HpLgtA, and elongated incubation, affording **34** in a yield of 78%. Mono-sulfated biantennary *O*-glycans **35**, **36**, and **37** were then prepared by sequential assembly using modules G, S1, and F1 (Fig. 3) in good to very good yields (75–86%). Finally, to synthesize the di-sulfated biantennary *O*-glycan found on GlyCAM-1 (**41**), CHST6 was used to sulfate the β 1-3linked GlcNAc (module Su6), given its much higher activity, affording the di-sulfated product (**38**) in an excellent yield of 91%. Subsequent sequential β 1-4galactosylation (module G), α 2-3sialylation (module S1), and α 1-3fucosylation (module F1) then afforded symmetric di-sulfated biantennary *O*-glycans **39**, **40**, and **41**, respectively, in good yields. Additionally, **42** was obtained by α 1-3fucosylation (module F1) of both branches of **39** in a nearly excellent yield (88%). Together, the results demonstrate the efficiency of this sequence-controlled enzymatic modular assembly for synthesizing complex sulfated glycans.

Modular assembly of sulfated *O*-mannosyl glycans

Many sulfated *O*-mannosyl glycans have been identified in brain tissues and mucins;^{19,24} however, only those containing the HNK-1 epitope have been synthesized to date.³⁴ To

showcase the broad applicability of the enzymatic assembly strategy, sulfated asymmetric *O*-mannosyl core m2 glycans were prepared. As illustrated in Fig. 4, a chemically prepared asymmetric core m2 glycan, **19**,⁴⁷ which carries a β 1-4Gal unit on the β 1-2GlcNAc branch, was used as the starting substrate to achieve selective sulfation and glycosylation. Treatment with module S2 selectively sulfated the β 1-6GlcNAc of **19** given the restricted recognition of terminal GlcNAc residues by CHST2, affording **43** in 81% yield. Subsequent α 2-6sialylation of the β 1-2GlcNAc branch (module S3) and β 1-4galactosylation of the β 1-6GlcNAc branch (module G) then gave **44** and **45** in 92% and 83% yields, respectively. Further treatment of **45** with module S3 yielded **46**. In addition, the reaction of **45** with module F1 enabled branch-selective α 1-3fucosylation of the β 1-6branch in 73% yield, as the α 2-6Neu5Ac on the β 1-2branch prevented Hp3FT-catalyzed fucosylation as expected.⁶³ Finally, desialylation of **47** using *A. ureafaciens* neuraminidase (AuNA) furnished the asymmetrically fucosylated and sulfated *O*-mannosyl glycan **48** in an excellent yield of 95%.

Enzymatic modular synthesis of a sulfated *O*-glycopeptide

We next sought to prepare the GlyCAM-1 glycopeptide presenting the di-sulfated biantennary *O*-glycan following the same synthetic route illustrated in Fig. 3 (from compounds **10** to **41**). As shown in Fig. 5, the synthesis began with solid-phase peptide synthesis (SSPS) by incorporating a peracetylated core 1-Thr building block⁴⁸ as the eleventh amino acid (Thr91), affording the GlyCAM-1 peptide (E_{81} TTRPTTSAAT $_{91}$ TSEENLT) bearing *O*-glycan core 1 (**49**). Subsequent treatment of **49** with module N2 (catalyzed by GCNT1) and module Su2 (catalyzed by CHST2) yielded the core 2 glycopeptide (**50**) and the 6-*O*-sulfated core 2 glycopeptide (**51**) in high yields of 85% and 91%, respectively. However, the following β 1-3GlcNAc extension catalyzed by HpLgtA (module N1) failed, giving less than 5% conversion even with excess donor, enzyme, and prolonged incubation, further indicating that HpLgtA activity is strongly affected by the surrounding structural context. Alternatively, **51** was elaborated to generate sulfated glycopeptides **52**, **53**, and **54** through sequential glycosylation with module S2 (catalyzed by ST3Gal1), module G (catalyzed by HpLgtB), and module S1 (catalyzed by ST3Gal4), affording desired products in very high yields of 84–92%. The inability of HpLgtA to act on glycopeptides also agrees with our observations that many bacterial-origin GTs exhibit poor activity on glycoconjugate substrates (unpublished). As an alternative, mammalian core 1-extending enzyme β 1-3-*N*-acetylglucosaminyltransferase 3 (B3GNT3)⁴ can be evaluated. In summary, while most established enzyme modules are readily applicable for the synthesis of glycopeptides or glycoproteins, certain modules empowered by bacterial GTs exhibit limited compatibility. The development of new synthetic modules employing mammalian glyco-related enzymes will further expand the synthetic toolbox for complex glycoconjugate assembly.




Fig. 4 Enzymatic modular assembly of asymmetric sulfated *O*-mannosyl glycans. Module G, β 1-4galactosylation catalyzed by HpLgtB in the presence of UDP-Gal; module Su2, GlcNAc-6-*O*-sulfation catalyzed by CHST2 in the presence of PAPS; module F1, α 1-3fucosylation catalyzed by Hp3FT in the presence of GDP-Fuc; module S3, α 2-6sialylation catalyzed by Pd26ST in the presence of CMP-Neu5Ac; AuNA, *A. ureafaciens* neuraminidase.⁵⁶






Fig. 5 Enzymatic modular synthesis of sulfated *O*-glycopeptides (A) and their MALDI-MS spectra (B). SPPS, solid-phase peptide synthesis; module N2, β 1-6GlcNAcylation catalyzed by GCNT1 in the presence of UDP-GlcNAc; module G, β 1-4galactosylation catalyzed by HpLgtB in the presence of UDP-Gal; module Su2, GlcNAc-6-*O*-sulfation catalyzed by CHST2 in the presence of PAPS; module S1, α 2-3sialylation catalyzed by human ST3Gal4 in the presence of CMP-Neu5Ac; module S2, α 2-3sialylation catalyzed by human ST3Gal1 in the presence of CMP-Neu5Ac.

Conclusion

We systematically studied the substrate specificity of two human GlcNAc-6-*O*-sulfotransferases and revealed their pronounced preference toward *O*-glycans, including mucin-type *O*-GalNAc and *O*-mannosyl glycans, over *N*-glycans and linear poly-LacNAc chains (keratan). A secondary but more important feature of their selectivity lies in their strong preference for the β 1-6 branching GlcNAc in *O*-glycans, but not I-branched GlcNAc. In comparison, CHST6 displayed higher overall activity toward nearly all tested structures than CHST2, except for the branching GlcNAc residues on *N*-glycans. Furthermore, CHST6 exhibited broader substrate tolerance, acting on various *O*-glycan cores and linear poly-LacNAc chains, whereas CHST2 showed very low or negligible activity toward GlcNAc residues on poly-LacNAc chains and β 1-2/3 branching GlcNAc on *O*-glycans. Notably, the activity of CHST6 diminishes in a

length-dependent manner toward the poly-LacNAc chain. These findings on substrate specificity and enzymatic activity provide valuable guidelines for the strategic employment of GlcNAc 6-*O*-sulfotransferases in the efficient synthesis of sulfated glycans.

Building on this knowledge, we developed an efficient modular assembly platform for the rapid synthesis of sulfated *O*-glycans and glycopeptides by integrating GT modules. Most enzyme modules demonstrated high efficiency toward both sulfated *O*-glycans and glycopeptides, whereas the bacterial HpLgtA module was incompatible with glycopeptide substrates. Another important observation is that all GTs employed in this study tolerated GlcNAc 6-*O*-sulfation, underscoring the compatibility of sulfation with subsequent enzymatic extensions. Overall, this modular assembly strategy provides a streamlined and versatile platform for synthesizing diverse sulfated *O*-glycans. Coupled with emerging methods



for large-scale PAPS synthesis⁶⁴ and regeneration,⁶⁵ our findings open the door to straightforward and scalable access to diverse sulfated glycans and glycoconjugates.

Author contributions

S. F. and L. L. conceived the project; S. F. performed enzyme assay and modular synthesis; J. H., T. S., and Z. D. helped with data interpretation; J. H., T. S., and A. I. performed chemical synthesis; J. P. G. B., and S. B. helped with enzymatic modular synthesis. L. L. and S. F. wrote the manuscript which was edited and approved by all authors.

Conflicts of interest

There are no conflicts to declare.

Data availability

The data supporting this article have been included as part of the supplementary information (SI). Supplementary information is available. See DOI: <https://doi.org/10.1039/d6qo00226a>.

Acknowledgements

The work was supported by the National Institutes of Health (NIH) grant R01GM152688. G. B. and S. B. are thankful for the support from the Molecular Basis of Disease (MBD) fellowship program at Georgia State University (GSU). T. S. is thankful for the support from the Center for Diagnostics & Therapeutics (CDT) fellowship program. We thank Dr Kelley Moremen from the University of Georgia for kindly providing human enzyme expression plasmids. Mass spectrometry analyses were conducted at GSU MS Facilities, which are partially supported by an NIH grant for the purchase of a Waters Xevo G2-XS mass spectrometer (1S10OD026764-01).

References

- 1 S. M. Muthana, C. T. Campbell and J. C. Gildersleeve, Modifications of glycans: biological significance and therapeutic opportunities, *ACS Chem. Biol.*, 2012, 7(1), 31–43, DOI: [10.1021/cb2004466](https://doi.org/10.1021/cb2004466).
- 2 D. S. da Costa, R. L. Reis and I. Pashkuleva, Sulfation of Glycosaminoglycans and Its Implications in Human Health and Disorders, *Annu. Rev. Biomed. Eng.*, 2017, 19, 1–26, DOI: [10.1146/annurev-bioeng-071516-044610](https://doi.org/10.1146/annurev-bioeng-071516-044610).
- 3 C. L. R. Merry, U. Lindahl, J. Couchman and J. D. Esko, Proteoglycans and Sulfated Glycosaminoglycans, in *Essentials of Glycobiology*, ed. A. Varki, R. D. Cummings, J. D. Esko, P. Stanley, G. W. Hart, M. Aebi, D. Mohnen, T. Kinoshita, N. H. Packer, J. H. Prestegard, *et al.*, 4th edn, 2022, pp. 217–232.
- 4 J. C. Yeh, N. Hiraoka, B. Petryniak, J. Nakayama, L. G. Ellies, D. Rabuka, O. Hindsgaul, J. D. Marth, J. B. Lowe and M. Fukuda, Novel sulfated lymphocyte homing receptors and their control by a Core1 extension beta 1,3-N-acetylglucosaminyltransferase, *Cell*, 2001, 105(7), 957–969, DOI: [10.1016/s0092-8674\(01\)00394-4](https://doi.org/10.1016/s0092-8674(01)00394-4).
- 5 G. H. Mir, J. Helin, K. P. Skarp, R. D. Cummings, A. Makitie, R. Renkonen and A. Leppanen, Glycoforms of human endothelial CD34 that bind L-selectin carry sulfated sialyl Lewis x capped O- and N-glycans, *Blood*, 2009, 114(3), 733–741, DOI: [10.1182/blood-2009-03-210237](https://doi.org/10.1182/blood-2009-03-210237).
- 6 S. Hemmerich, H. Leffler and S. D. Rosen, Structure of the O-glycans in GlyCAM-1, an endothelial-derived ligand for L-selectin, *J. Biol. Chem.*, 1995, 270(20), 12035–12047, DOI: [10.1074/jbc.270.20.12035](https://doi.org/10.1074/jbc.270.20.12035).
- 7 K. Uchimura and S. D. Rosen, Sulfated L-selectin ligands as a therapeutic target in chronic inflammation, *Trends Immunol.*, 2006, 27(12), 559–565, DOI: [10.1016/j.it.2006.10.007](https://doi.org/10.1016/j.it.2006.10.007).
- 8 S. D. Rosen, Ligands for L-selectin: homing, inflammation, and beyond, *Annu. Rev. Immunol.*, 2004, 22, 129–156, DOI: [10.1146/annurev.immunol.21.090501.080131](https://doi.org/10.1146/annurev.immunol.21.090501.080131).
- 9 B. Xia, J. A. Royall, G. Damera, G. P. Sachdev and R. D. Cummings, Altered O-glycosylation and sulfation of airway mucins associated with cystic fibrosis, *Glycobiology*, 2005, 15(8), 747–775, DOI: [10.1093/glycob/cwi061](https://doi.org/10.1093/glycob/cwi061).
- 10 K. A. Thomsson, V. Vitiazeva, C. Mateoiu, C. Jin, J. Liu, J. Holgersson, B. Weijdegard, K. Sundfeldt and N. G. Karlsson, Sulfation of O-glycans on Mucin-type Proteins From Serous Ovarian Epithelial Tumors, *Mol. Cell. Proteomics*, 2021, 20, 100150, DOI: [10.1016/j.mcpro.2021.100150](https://doi.org/10.1016/j.mcpro.2021.100150).
- 11 K. Yamada, K. Asada, K. Hanzawa, Y. Aoki, K. Nakajima and M. Kinoshita, Developing Method for Minor Acidic O-Glycan Analysis in Mucin and Cancer Cell Samples, *J. Proteome Res.*, 2024, 23(10), 4254–4272, DOI: [10.1021/acs.jproteome.4c00240](https://doi.org/10.1021/acs.jproteome.4c00240).
- 12 K. Madunic, T. Zhang, O. A. Mayboroda, S. Holst, K. Stavenhagen, C. Jin, N. G. Karlsson, G. S. M. Lageveen-Kammeijer and M. Wuhler, Colorectal cancer cell lines show striking diversity of their O-glycome reflecting the cellular differentiation phenotype, *Cell. Mol. Life Sci.*, 2021, 78(1), 337–350, DOI: [10.1007/s00018-020-03504-z](https://doi.org/10.1007/s00018-020-03504-z).
- 13 M. Tanaka-Okamoto, M. Mukai, H. Takahashi, Y. Fujiwara, M. Ohue and Y. Miyamoto, Various sulfated carbohydrate tumor marker candidates identified by focused glycomic analyses, *Glycobiology*, 2017, 27(5), 400–415, DOI: [10.1093/glycob/cww133](https://doi.org/10.1093/glycob/cww133).
- 14 A. S. Luis, A. Basle, D. P. Byrne, G. S. A. Wright, J. A. London, C. Jin, N. G. Karlsson, G. C. Hansson, P. A. Eyers, M. Czjzek, *et al.*, Sulfated glycan recognition by carbohydrate sulfatases of the human gut microbiota, *Nat. Chem. Biol.*, 2022, 18(8), 841–849, DOI: [10.1038/s41589-022-01039-x](https://doi.org/10.1038/s41589-022-01039-x).



- 15 N. G. Karlsson, H. Karlsson and G. C. Hansson, Sulphated mucin oligosaccharides from porcine small intestine analysed by four-sector tandem mass spectrometry, *J. Mass Spectrom.*, 1996, **31**(5), 560–572, DOI: [10.1002/\(SICI\)1096-9888\(199605\)31:5<560::AID-JMS331>3.0.CO;2-0](https://doi.org/10.1002/(SICI)1096-9888(199605)31:5<560::AID-JMS331>3.0.CO;2-0).
- 16 N. G. Karlsson, M. E. Johansson, N. Asker, H. Karlsson, S. J. Gendler, I. Carlstedt and G. C. Hansson, Molecular characterization of the large heavily glycosylated domain glycopeptide from the rat small intestinal Muc2 mucin, *Glycoconjugate J.*, 1996, **13**(5), 823–831, DOI: [10.1007/BF00702346](https://doi.org/10.1007/BF00702346).
- 17 B. L. Slomiany, V. L. Murty and A. Slomiany, Structural features of carbohydrate chains in human salivary mucins, *Int. J. Biochem.*, 1993, **25**(2), 259–265, DOI: [10.1016/0020-711x\(93\)90015-7](https://doi.org/10.1016/0020-711x(93)90015-7).
- 18 T. P. Mawhinney, D. C. Landrum, D. A. Gayer and G. J. Barbero, Sulfated sialyl-oligosaccharides derived from tracheobronchial mucous glycoproteins of a patient suffering from cystic fibrosis, *Carbohydr. Res.*, 1992, **235**, 179–197, DOI: [10.1016/0008-6215\(92\)80087-h](https://doi.org/10.1016/0008-6215(92)80087-h).
- 19 A. S. Luis, C. Jin, G. V. Pereira, R. W. P. Glowacki, S. R. Gugel, S. Singh, D. P. Byrne, N. A. Pudlo, J. A. London, A. Basle, *et al.*, A single sulfatase is required to access colonic mucin by a gut bacterium, *Nature*, 2021, **598**(7880), 332–337, DOI: [10.1038/s41586-021-03967-5](https://doi.org/10.1038/s41586-021-03967-5).
- 20 S. H. Stalnakar, K. Aoki, J. M. Lim, M. Porterfield, M. Liu, J. S. Satz, S. Buskirk, Y. Xiong, P. Zhang, K. P. Campbell, *et al.*, Glycomic analyses of mouse models of congenital muscular dystrophy, *J. Biol. Chem.*, 2011, **286**(24), 21180–21190, DOI: [10.1074/jbc.M110.203281](https://doi.org/10.1074/jbc.M110.203281).
- 21 C. T. Yuen, W. Chai, R. W. Loveless, A. M. Lawson, R. U. Margolis and T. Feizi, Brain contains HNK-1 immunoreactive O-glycans of the sulfoglucuronyl lactosamine series that terminate in 2-linked or 2,6-linked hexose (mannose), *J. Biol. Chem.*, 1997, **272**(14), 8924–8931, DOI: [10.1074/jbc.272.14.8924](https://doi.org/10.1074/jbc.272.14.8924).
- 22 C. A. Dwyer, T. Katoh, M. Tiemeyer and R. T. Matthews, Neurons and glia modify receptor protein-tyrosine phosphatase zeta (RPTPzeta)/phosphacan with cell-specific O-mannosyl glycans in the developing brain, *J. Biol. Chem.*, 2015, **290**(16), 10256–10273, DOI: [10.1074/jbc.M114.614099](https://doi.org/10.1074/jbc.M114.614099).
- 23 J. Morise, Y. Kizuka, K. Yabuno, Y. Tonoyama, N. Hashii, N. Kawasaki, H. Manya, Y. Miyagoe-Suzuki, S. Takeda, T. Endo, *et al.*, Structural and biochemical characterization of O-mannose-linked human natural killer-1 glycan expressed on phosphacan in developing mouse brains, *Glycobiology*, 2014, **24**(3), 314–324, DOI: [10.1093/glycob/cwt116](https://doi.org/10.1093/glycob/cwt116).
- 24 H. Wilkinson, K. A. Thomsson, A. L. Rebelo, M. Hilliard, A. Pandit, P. M. Rudd, N. G. Karlsson and R. Saldiva, The O-Glycome of Human Nigrostriatal Tissue and Its Alteration in Parkinson's Disease, *J. Proteome Res.*, 2021, **20**(8), 3913–3924, DOI: [10.1021/acs.jproteome.1c00219](https://doi.org/10.1021/acs.jproteome.1c00219).
- 25 P. Stanley, M. Wuhler, G. Lauc, S. R. Stowell and R. D. Cummings, Structures Common to Different Glycans, in *In Essentials of Glycobiology*, ed. A. Varki, R. D. Cummings, J. D. Esko, P. Stanley, G. W. Hart, M. Aebi, D. Mohnen, T. Kinoshita, N. H. Packer, J. H. Prestegard, *et al.*, 4th edn, 2022, pp. 165–184.
- 26 R. D. Cummings, The repertoire of glycan determinants in the human glycome, *Mol. Biosyst.*, 2009, **5**(10), 1087–1104, DOI: [10.1039/b907931a](https://doi.org/10.1039/b907931a).
- 27 J. Morise, H. Takematsu and S. Oka, The role of human natural killer-1 (HNK-1) carbohydrate in neuronal plasticity and disease, *Biochim. Biophys. Acta, Gen. Subj.*, 2017, **1861**(10), 2455–2461, DOI: [10.1016/j.bbagen.2017.06.025](https://doi.org/10.1016/j.bbagen.2017.06.025).
- 28 N. Ertunc, T. Phitak, D. Wu, H. Fujita, M. Hane, C. Sato and K. Kitajima, Sulfation of sialic acid is ubiquitous and essential for vertebrate development, *Sci. Rep.*, 2022, **12**(1), 12496, DOI: [10.1038/s41598-022-15143-4](https://doi.org/10.1038/s41598-022-15143-4).
- 29 J. Jung, E. N. Schmidt and M. S. Macauley, Carbohydrate sulfation as a critical modulator of siglec-sialoglycan interactions, *Carbohydr. Res.*, 2025, **553**, 109502, DOI: [10.1016/j.carres.2025.109502](https://doi.org/10.1016/j.carres.2025.109502).
- 30 J. Jung, E. N. Schmidt, H. C. Chang, Z. Jame-Chenarboo, J. R. Enterina, K. A. McCord, T. E. Gray, L. Kageler, C. D. St Laurent, C. Wang, *et al.*, Understanding the Glycosylation Pathways Involved in the Biosynthesis of the Sulfated Glycan Ligands for Siglecs, *ACS Chem. Biol.*, 2025, **20**(2), 386–400, DOI: [10.1021/acscchembio.4c00677](https://doi.org/10.1021/acscchembio.4c00677).
- 31 C. Bull, R. Nason, L. Sun, J. V. Coillie, D. M. Sorensen, S. J. Moons, Z. Yang, S. Arbitman, S. M. Fernandes, S. Furukawa, *et al.*, Probing the binding specificities of human Siglecs by cell-based glycan arrays, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**(17), e2026102118, DOI: [10.1073/pnas.2026102118](https://doi.org/10.1073/pnas.2026102118).
- 32 S. Ma, P. Zhang, J. Ye, Y. Tian, X. Tian, J. Jung, M. S. Macauley, J. Zhang, P. Wu and L. Wen, Enzyme-Sialylation-Controlled Chemical Sulfation of Glycan Epitopes for Decoding the Binding of Siglec Ligands, *J. Am. Chem. Soc.*, 2024, **146**(43), 29469–29480, DOI: [10.1021/jacs.4c08817](https://doi.org/10.1021/jacs.4c08817).
- 33 A. Santra, H. Yu, N. Tasnima, M. M. Muthana, Y. Li, J. Zeng, N. J. Kenyond, A. Y. Louie and X. Chen, Systematic Chemoenzymatic Synthesis of O-Sulfated Sialyl Lewis x Antigens, *Chem. Sci.*, 2016, **7**(4), 2827–2831, DOI: [10.1039/C5SC04104J](https://doi.org/10.1039/C5SC04104J).
- 34 T. Gao, J. Yan, C. C. Liu, A. S. Palma, Z. Guo, M. Xiao, X. Chen, X. Liang, W. Chai and H. Cao, Chemoenzymatic Synthesis of O-Mannose Glycans Containing Sulfated or Nonsulfated HNK-1 Epitope, *J. Am. Chem. Soc.*, 2019, **141**(49), 19351–19359, DOI: [10.1021/jacs.9b08964](https://doi.org/10.1021/jacs.9b08964).
- 35 Z. Xu, Y. Liu, J. Liu, W. Ma, Z. Zhang, D. G. Chapla, L. Wen, K. W. Moremen, W. Yi and T. Li, Integrated chemoenzymatic synthesis of a comprehensive sulfated ganglioside glycan library to decipher functional sulfoglycomics and sialoglycomics, *Nat. Chem.*, 2024, **16**(6), 881–892, DOI: [10.1038/s41557-024-01540-x](https://doi.org/10.1038/s41557-024-01540-x).
- 36 M. I. Bunyatov and G. J. Boons, Chemoenzymatic Synthesis of Glycosphingolipids Having an HNK-1 Epitope for



- Erythrocyte Cell Surface Remodeling, *J. Am. Chem. Soc.*, 2025, **147**(29), 25306–25315, DOI: [10.1021/jacs.5c04179](https://doi.org/10.1021/jacs.5c04179).
- 37 M. I. Bunyatov, M. A. Wolfert and G. J. Boons, Divergent Chemoenzymatic Synthesis of Sulfated Ganglio-Oligosaccharides for Probing Ligand Requirements of Glycan Binding Proteins, *Angew. Chem., Int. Ed.*, 2025, **64**(11), e202415521, DOI: [10.1002/anie.202415521](https://doi.org/10.1002/anie.202415521).
- 38 Z. Xu, Y. Deng, Z. Zhang, W. Ma, W. Li, L. Wen and T. Li, Diversity-Oriented Chemoenzymatic Synthesis of Sulfated and Nonsulfated Core 2 O-GalNAc Glycans, *J. Org. Chem.*, 2021, **86**(15), 10819–10828, DOI: [10.1021/acs.joc.1c01115](https://doi.org/10.1021/acs.joc.1c01115).
- 39 Y. Wu, G. M. Vos, C. Huang, D. Chapla, A. L. M. Kimpel, K. W. Moremen, R. P. de Vries and G. J. Boons, Exploiting Substrate Specificities of 6-O-Sulfotransferases to Enzymatically Synthesize Keratan Sulfate Oligosaccharides, *JACS Au*, 2023, **3**(11), 3155–3164, DOI: [10.1021/jacsau.3c00488](https://doi.org/10.1021/jacsau.3c00488).
- 40 Y. Wu, G. P. Bosman, D. Chapla, C. Huang, K. W. Moremen, R. P. de Vries and G. J. Boons, A Biomimetic Synthetic Strategy Can Provide Keratan Sulfate I and II Oligosaccharides with Diverse Fucosylation and Sulfation Patterns, *J. Am. Chem. Soc.*, 2024, **146**(13), 9230–9240, DOI: [10.1021/jacs.4c00363](https://doi.org/10.1021/jacs.4c00363).
- 41 K. Huang, E. E. Bashian, G. Zong, C. M. Nycholat, R. McBride, M. Gomozkova, S. Wang, C. Huang, D. G. Chapla, E. N. Schmidt, *et al.*, Chemoenzymatic Synthesis of Sulfated N-Glycans Recognized by Siglecs and Other Glycan-Binding Proteins, *JACS Au*, 2024, **4**(8), 2966–2978, DOI: [10.1021/jacsau.4c00307](https://doi.org/10.1021/jacsau.4c00307).
- 42 K. Huang, C. Li, G. Zong, S. K. Prabhu, D. G. Chapla, K. W. Moremen and L. X. Wang, Site-selective sulfation of N-glycans by human GlcNAc-6-O-sulfotransferase 1 (CHST2) and chemoenzymatic synthesis of sulfated antibody glycoforms, *Bioorg. Chem.*, 2022, **128**, 106070, DOI: [10.1016/j.bioorg.2022.106070](https://doi.org/10.1016/j.bioorg.2022.106070).
- 43 S. Ma, J. Zhang, F. Wei, X. Tian, Y. Tian and L. Wen, De Novo Chemoenzymatic Assembly of Complex Sulfated N-Glycans to Comprehensively Profile the Ligand Binding of Human Siglecs, *J. Am. Chem. Soc.*, 2025, 35042–35054, DOI: [10.1021/jacs.5c11949](https://doi.org/10.1021/jacs.5c11949).
- 44 R. K. Bains, F. Liu, S. A. Nasser, J. F. Wardman and S. G. Withers, Streamlining Sulfated Oligosaccharide and Glycan Synthesis with Engineered Mutant 6-SulfoGlcNAcases, *J. Am. Chem. Soc.*, 2025, **147**(7), 5554–5559, DOI: [10.1021/jacs.4c14102](https://doi.org/10.1021/jacs.4c14102).
- 45 M. R. Gadi, C. Chen, S. Bao, S. Wang, Y. Guo, J. Han, W. Xiao and L. Li, Convergent chemoenzymatic synthesis of O-GalNAc rare cores 5, 7, 8 and their sialylated forms, *Chem. Sci.*, 2023, **14**(7), 1837–1843, DOI: [10.1039/d2sc06925c](https://doi.org/10.1039/d2sc06925c).
- 46 S. Wang, C. Chen, M. R. Gadi, V. Saikam, D. Liu, H. Zhu, R. Bollag, K. Liu, X. Chen, F. Wang, *et al.*, Chemoenzymatic modular assembly of O-GalNAc glycans for functional glycomics, *Nat. Commun.*, 2021, **12**(1), 3573, DOI: [10.1038/s41467-021-23428-x](https://doi.org/10.1038/s41467-021-23428-x).
- 47 S. Wang, Q. Zhang, C. Chen, Y. Guo, M. R. Gadi, J. Yu, U. Westerlind, Y. Liu, X. Cao, P. G. Wang and L. Li, Facile Chemoenzymatic Synthesis of O-Mannosyl Glycans, *Angew. Chem., Int. Ed.*, 2018, **57**(30), 9268–9273, DOI: [10.1002/anie.201803536](https://doi.org/10.1002/anie.201803536).
- 48 M. R. Gadi, J. Han, T. Shen, S. Fan, Z. Xiao and L. Li, Divergent synthesis of amino acid-linked O-GalNAc glycan core structures, *Nat. Protoc.*, 2025, **20**(2), 480–517, DOI: [10.1038/s41596-024-01051-6](https://doi.org/10.1038/s41596-024-01051-6).
- 49 T. O. Akama, A. K. Misra, O. Hindsgaul and M. N. Fukuda, Enzymatic synthesis in vitro of the disulfated disaccharide unit of corneal keratan sulfate, *J. Biol. Chem.*, 2002, **277**(45), 42505–42513, DOI: [10.1074/jbc.M207412200](https://doi.org/10.1074/jbc.M207412200).
- 50 K. Uchimura, F. M. El-Fasakhany, M. Hori, S. Hemmerich, S. E. Blink, G. S. Kansas, A. Kanamori, K. Kumamoto, R. Kannagi and T. Muramatsu, Specificities of N-acetylglucosamine-6-O-sulfotransferases in relation to L-selectin ligand synthesis and tumor-associated enzyme expression, *J. Biol. Chem.*, 2002, **277**(6), 3979–3984, DOI: [10.1074/jbc.M106587200](https://doi.org/10.1074/jbc.M106587200).
- 51 K. Uchimura, H. Muramatsu, K. Kadomatsu, Q. W. Fan, N. Kurosawa, C. Mitsuoka, R. Kannagi, O. Habuchi and T. Muramatsu, Molecular cloning and characterization of an N-acetylglucosamine-6-O-sulfotransferase, *J. Biol. Chem.*, 1998, **273**(35), 22577–22583, DOI: [10.1074/jbc.273.35.22577](https://doi.org/10.1074/jbc.273.35.22577).
- 52 S. Degroote, J. M. Lo-Guidice, G. Strecker, M. P. Ducourouble, P. Roussel and G. Lamblin, Characterization of an N-acetylglucosamine-6-O-sulfotransferase from human respiratory mucosa active on mucin carbohydrate chains, *J. Biol. Chem.*, 1997, **272**(47), 29493–29501, DOI: [10.1074/jbc.272.47.29493](https://doi.org/10.1074/jbc.272.47.29493).
- 53 K. Uchimura, F. Fasakhany, K. Kadomatsu, T. Matsukawa, T. Yamakawa, N. Kurosawa and T. Muramatsu, Diversity of N-acetylglucosamine-6-O-sulfotransferases: molecular cloning of a novel enzyme with different distribution and specificities, *Biochem. Biophys. Res. Commun.*, 2000, **274**(2), 291–296, DOI: [10.1006/bbrc.2000.3141](https://doi.org/10.1006/bbrc.2000.3141).
- 54 H. Kitagawa, M. Fujita, N. Ito and K. Sugahara, Molecular cloning and expression of a novel chondroitin 6-O-sulfotransferase, *J. Biol. Chem.*, 2000, **275**(28), 21075–21080, DOI: [10.1074/jbc.M002101200](https://doi.org/10.1074/jbc.M002101200).
- 55 K. W. Moremen, A. Ramiah, M. Stuart, J. Steel, L. Meng, F. Forouhar, H. A. Moniz, G. Gahlay, Z. Gao, D. Chapla, *et al.*, Expression system for structural and functional studies of human glycosylation enzymes, *Nat. Chem. Biol.*, 2018, **14**(2), 156–162, DOI: [10.1038/nchembio.2539](https://doi.org/10.1038/nchembio.2539).
- 56 S. Bao, T. Shen, C. Chen, J. Han, V. Tajadura-Ortega, M. Shabahang, Z. Du, T. Feizi, W. Chai and L. Li, Orthogonal-Group-Controlled Site-Selective I-Branching of Poly-N-acetylglucosamine Chains Reveals Unique Binding Specificities of Proteins towards I-Antigens, *Angew. Chem., Int. Ed.*, 2025, **64**(11), e202420676, DOI: [10.1002/anie.202420676](https://doi.org/10.1002/anie.202420676).
- 57 W. Peng, J. Pranskevich, C. Nycholat, M. Gilbert, W. Wakarchuk, J. C. Paulson and N. Razi, Helicobacter



- pylori beta1,3-N-acetylglucosaminyltransferase for versatile synthesis of type 1 and type 2 poly-LacNAcs on N-linked, O-linked and I-antigen glycans, *Glycobiology*, 2012, 22(11), 1453–1464, DOI: [10.1093/glycob/cws101](https://doi.org/10.1093/glycob/cws101).
- 58 Y. Li, M. Xue, X. Sheng, H. Yu, J. Zeng, V. Thon, Y. Chen, M. M. Muthana, P. G. Wang and X. Chen, Donor substrate promiscuity of bacterial beta1–3-N-acetylglucosaminyltransferases and acceptor substrate flexibility of beta1–4-galactosyltransferases, *Bioorg. Med. Chem.*, 2016, 24(8), 1696–1705, DOI: [10.1016/j.bmc.2016.02.043](https://doi.org/10.1016/j.bmc.2016.02.043).
- 59 K. Lau, V. Thon, H. Yu, L. Ding, Y. Chen, M. M. Muthana, D. Wong, R. Huang and X. Chen, Highly efficient chemoenzymatic synthesis of beta1–4-linked galactosides with promiscuous bacterial beta1–4-galactosyltransferases, *Chem. Commun.*, 2010, 46(33), 6066–6068, DOI: [10.1039/c0cc01381a](https://doi.org/10.1039/c0cc01381a).
- 60 S. W. Lin, T. M. Yuan, J. R. Li and C. H. Lin, Carboxyl terminus of *Helicobacter pylori* alpha1,3-fucosyltransferase determines the structure and stability, *Biochemistry*, 2006, 45(26), 8108–8116, DOI: [10.1021/bi0601297](https://doi.org/10.1021/bi0601297).
- 61 Y. Liu, L. Wen, L. Li, M. R. Gadi, W. Guan, K. Huang, Z. Xiao, M. Wei, C. Ma, Q. Zhang, *et al.*, A General Chemoenzymatic Strategy for the Synthesis of Glycosphingolipids, *European J. Org. Chem.*, 2016, 25, 4315–4320, DOI: [10.1002/ejoc.201600950](https://doi.org/10.1002/ejoc.201600950).
- 62 G. Sugiarto, K. Lau, J. Qu, Y. Li, S. Lim, S. Mu, J. B. Ames, A. J. Fisher and X. Chen, A sialyltransferase mutant with decreased donor hydrolysis and reduced sialidase activities for directly sialylating LewisX, *ACS Chem. Biol.*, 2012, 7(7), 1232–1240, DOI: [10.1021/cb300125k](https://doi.org/10.1021/cb300125k).
- 63 L. Li, Y. Liu, C. Ma, J. Qu, A. D. Calderon, B. Wu, N. Wei, X. Wang, Y. Guo, Z. Xiao, *et al.*, Efficient Chemoenzymatic Synthesis of an N-glycan Isomer Library, *Chem. Sci.*, 2015, 6(10), 5652–5661, DOI: [10.1039/C5SC02025E](https://doi.org/10.1039/C5SC02025E).
- 64 R. Xu, Y. Wang, H. Huang, X. Jin, J. Li, G. Du and Z. Kang, Closed-loop system driven by ADP phosphorylation from pyrophosphate affords equimolar transformation of ATP to 3'-phosphoadenosine-5'-phosphosulfate, *ACS Catal.*, 2021, 11(16), 10405–10415, DOI: [10.1021/acscatal.1c02004](https://doi.org/10.1021/acscatal.1c02004).
- 65 R. Xu, W. Zhang, X. Xi, J. Chen, Y. Wang, G. Du, J. Li, J. Chen and Z. Kang, Engineering sulfonate group donor regeneration systems to boost biosynthesis of sulfated compounds, *Nat. Commun.*, 2023, 14(1), 7297, DOI: [10.1038/s41467-023-43195-1](https://doi.org/10.1038/s41467-023-43195-1).

